StageZero Life Sciences (TSX:SZLS) Total Inventories : C$0.03 Mil (As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences Total Inventories?

StageZero Life Sciences's total inventories for the quarter that ended in Sep. 2023 was C$0.03 Mil. StageZero Life Sciences's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Sep. 2023 was C$0.07 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. StageZero Life Sciences's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was C$-0.10.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. StageZero Life Sciences's Days Inventory for the three months ended in Sep. 2023 was 8.24.

Inventory Turnover measures how fast the company turns over its inventory within a year. StageZero Life Sciences's Inventory Turnover for the quarter that ended in Sep. 2023 was 11.08.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. StageZero Life Sciences's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 0.07.

StageZero Life Sciences Total Inventories Historical Data

The historical data trend for StageZero Life Sciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Total Inventories Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Inventories

Get a 7-Day Free Trial

0.15

0.12

0.46

0.52

0.13

StageZero Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Inventories	Get a 7-Day Free Trial															0.32	0.13	0.11	0.11	0.03

StageZero Life Sciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

StageZero Life Sciences (TSX:SZLS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

StageZero Life Sciences's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is

	Net-Net Working Capital Per Share (Q: Sep. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.032	+	0.75 * 0.111	+	0.5 * 0.031	-	12.967
-	0	-	0)	/	122.717
=	-0.10

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

StageZero Life Sciences's Days Inventory for the three months ended in Sep. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2023 )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
	=	0.0705	/	0.781	*	365 / 4
	=	8.24

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

StageZero Life Sciences's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2023 )	/	Average Total Inventories (Q: Sep. 2023 )
	=	0.781	/	0.0705
	=	11.08

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

StageZero Life Sciences's Inventory to Revenue for the quarter that ended in Sep. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	0.0705	/	1.008
	=	0.07

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

StageZero Life Sciences Total Inventories Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences (TSX:SZLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

SZLSF:USA 61N1:Germany

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines